BioPharma Dive January 31, 2023
Rebecca Pifer

Dive Brief:

  • Drugmakers are allowed to restrict healthcare providers’ use of community and specialty pharmacies to dispense drugs in the 340B drug discount program, a federal appeals court ruled Monday.
  • The decision is a win for Sanofi, Novo Nordisk and AstraZeneca. The drugmakers had sued the Department of Health and Human Services after regulators ordered them to stop restricting sales of 340B drugs to contract pharmacies.
  • The three-judge panel’s decision reverses a previous ruling in New Jersey against Novo Nordisk and Sanofi, and upholds one from Delaware in favor of AstraZeneca. It’s the first decision from three federal appeals courts that are considering lawsuits over the pharmaceutical companies’ 340B restrictions.

Dive Insight:

Healthcare providers and drugmakers have been...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, HHS, Pharma, Pharma / Biotech
Related Articles:
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations

Share This Article